# US 10,004,796 B2 · Adenoviral vector-based vaccine against enterovirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,004,796 B2
- Document ID: US10004796B2
- Status: Granted
- Kind: B2
- Application number: 15/307,926
- Filed: 2015-03-26
- Published: 2017-03-02
- Granted: 2018-06-26
- Earliest claimed: 2014-04-29
- Assignees: National Health Research Institutes
- Applicants: National Health Research Institutes
- Inventors: Yen-Hung Chow; Yueh-Liang Tsou; Pele Choi-Sing Chong
- Web page: https://patentgrep.com/patent/US10004796B2

## CPC

- A61K 39/125: Picornaviridae, e.g. calicivirus
- A61K 39/12: Viral antigens
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2710/10323: Virus like particles [VLP]
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2770/32323: Virus like particles [VLP]
- C12N 2770/32334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32351: Methods of production or purification of viral material
- C12N 2770/32371: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

## Claims

### Claim 1

A method of inducing an immune response in a subject against enterovirus infection, comprising administering to the subject an effective amount of a recombinant adenoviral vector, which comprises an expression cassette comprising the nucleic acid sequence of SEQ ID NO: 3 or 4.

### Claim 2 (depends on 1)

The method of claim 1, wherein the recombinant adenoviral vector is replication deficient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the recombinant adenoviral vector is formulated in a vaccine composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the enterovirus infection is caused by enterovirus 71 or coxsackievirus A group.

### Claim 5 (depends on 1)

The method of claim 1, wherein the recombinant adenoviral vector is administered subcutaneously, nasally, intraperitoneally or orally.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administering is repeated.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immune response includes T cell responses against the enterovirus infection.

### Claim 8 (depends on 7)

The method of claim 7, wherein the T cell response is 3C or 3CD specific.